Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3;148(9):3340-3349.
doi: 10.1093/brain/awaf211.

Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults

Affiliations

Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults

Lei Yu et al. Brain. .

Abstract

There has been a rapid growth in research on peripheral fluid biomarkers for Alzheimer's disease (AD) and AD-related dementias, because they are non-invasive, relatively inexpensive and easily accessible. The most commonly used plasma biomarkers include amyloid-β (Aβ), phosphorylated tau (p-tau), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). The extent to which distinct profiles of multiple plasma biomarkers correlate with common neuropathologies is unclear. Using clinicopathologic data from 405 community-dwelling older adults, we applied latent profile analysis to four plasma biomarkers, i.e. Aβ42/40 ratio, p-tau217, NfL and GFAP, and examined the correlates of the latent profiles with four degeneration measures: AD, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and hippocampal sclerosis; and five vascular measures: chronic macroscopic infarcts, microinfarcts, cerebral amyloid angiopathy, atherosclerosis and arteriosclerosis. On average, participants died at the age of 89, and blood samples for plasma biomarkers were measured 3.9 years before death. Over 75% were female, and 24% were non-Latino Black. We observed three distinct biomarker profiles. Profile 1, characterized by low p-tau217, low GFAP, low NfL and high Aβ42/40, represented most participants (55.6%), with better than average biomarker levels. Both Profile 2 and Profile 3 showed worse than average biomarker levels. Profile 2, representing 34.8% of the participants, was high in p-tau217 and GFAP. In contrast, Profile 3, representing 9.6% of the participants, was high in NfL and GFAP. Examination of neuropathologic correlates of these plasma biomarker profiles revealed that Profile 2 exemplifies older adults with a high burden of neurodegeneration; almost all participants (92.9%) in Profile 2 had a diagnosis of pathologic AD, and the group also had the highest percentage of participants with Lewy bodies (41.1%). In comparison, Profile 3 exemplifies older adults with more severe vascular conditions; participants in this group had the highest percentage of macroscopic infarcts (31.6%) and moderate or severe atherosclerosis (42.1%). Together, these findings suggest that common plasma biomarkers may exhibit profiles reflective of distinct pathophysiologic processes.

Keywords: AD/ADRD; cerebrovascular conditions; latent profile analysis; neurodegeneration; plasma biomarkers.

PubMed Disclaimer

Conflict of interest statement

J.L.D. is an inventor on patents or patent applications assigned to Eli Lilly and Company relating to the assays, methods, reagents and/or compositions of matter for P-tau assays and Aβ targeting therapeutics. JLD has/is served/serving as a consultant or on advisory boards for Eisai, Abbvie, Genotix Biotechnologies Inc, Gates Ventures, Gate Neurosciences, Dolby Family Ventures, Karuna Therapeutics, Alzheimer’s Disease Drug Discovery Foundation, AlzPath Inc., Cognito Therapeutics, Inc., Eli Lilly and Company, Prevail Therapeutics, Neurogen Biomarking, Spear Bio, Rush University, University of Kentucky, Tymora Analytical Operations, and Quanterix. JLD has received research support from ADx Neurosciences, Fujirebio, Roche Diagnostics and Eli Lilly and Company in the past two years. JLD has received speaker fees from Eli Lilly and Company and LabCorp. J.L.D. is a founder and advisor for Monument Biosciences and Dage Scientific LLC. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, AlzPath Inc., Neurogen Biomarking, and Monument Biosciences. All other authors report no competing interests.

Comment in

References

    1. Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547. - PMC - PubMed
    1. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–e1659. - PMC - PubMed
    1. Li Y, Schindler SE, Bollinger JG, et al. Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98:e688–e699. - PMC - PubMed
    1. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772–781. - PMC - PubMed
    1. Mielke MM, Frank RD, Dage JL, et al. Comparison of plasma phosphorylated tau Species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78:1108–1117. - PMC - PubMed

LinkOut - more resources